Detailed Narrative
Q1 FY26 Performance Overview
Zydus Wellness reported a consolidated net sales growth of 2.2% to ₹8,577 million for Q1 FY26. EBITDA saw a modest growth of 0.2% to ₹1,556 million, while PAT declined by 13.4% primarily due to non-cash items like amortization and deferred tax. The company highlighted that excluding seasonal brands, it achieved strong double-digit growth, indicating underlying portfolio strength despite overall challenges.
Seasonal Impact and Underlying Growth
The quarter's performance was significantly affected by a shorter summer and unseasonal rains, which impacted seasonal brands like Nycil and Glucon D. Management noted that the impact was largely contained to Q1, with minimal spillover expected into Q3. Despite these seasonal headwinds, the non-seasonal portfolio remained strong, cushioning overall performance and contributing to the double-digit growth when seasonal brands are excluded.
Margin Dynamics and Cost Management
Gross margins experienced a marginal decline of 73 basis points during the quarter. This was primarily attributed to product mix issues. However, management expressed optimism for margin recovery in coming quarters, citing easing input inflation and proactive strategic hedging. They emphasized ongoing product-by-product gross margin expansion efforts and expected operating leverage to play out as the business scales, contributing to improved EBITDA margins.
Distribution and Channel Strategy
Organized trade saliency continued to improve, reaching 30.9% in Q1 FY26, up from 23.3% in Q1 FY25, driven by the amalgamation of new businesses with substantial quick commerce and e-commerce presence. The company aims to expand its direct reach to 7 lakh outlets by the end of the financial year, planning to add 80,000 new outlets. This strategy balances investment in traditional general trade, particularly in smaller towns and rural areas, with growing digital channels.
Brand Performance and Portfolio Diversification
The personal care segment grew 3.8% YoY, with EverYuth showing consistent double-digit growth and leading key sub-segments. Nycil maintained its number one position with a 33.3% market share despite seasonal dips. Glucon D held its leadership in glucose powder with a 58.9% market share. Sugar Free continued its dominance with a 96.1% market share. The acquired Rite Bite Max Protein business is outperforming earlier estimates, reinforcing its strategic value and contributing robust growth.
HFD Category Challenges and Complan's Future
The Health Food Drink (HFD) category, including Complan, faces challenges as consumers seek nutrition from diverse sources, leading to a 2.6% decline at the MAT level. Complan's market share has decreased from 5-5.5% in June 2019 to 4.0% in June 2025. Management expects the category to deliver low single-digit growth in the medium to long term and indicated that strategic calls would be made in the next couple of years if the current strategy of offering premium, superior products does not yield desired results.
Taxation Outlook
The company provided clear guidance on its future tax rates. For the current fiscal year, FY25-26, there will be zero tax. For the subsequent year, FY26-27, a marginal tax rate of 8-10% is anticipated. Following that, for FY27-28 and beyond, the company expects to revert to a full tax rate of 25%. This provides clarity for financial modeling and future profitability projections.